CD4 and myeloid sarcoma: An elevated number of DNAme groups to MORN repeat containing 1 (MORN1) has been reported in both CD4+ and CD8+ T cells collected from MS patients (Graves et al., 2014; Maltby et al., 2015) and might affect T cell viability (Woo et al., 2016).